Q1 Earnings Estimate for OptimizeRx Issued By B. Riley

OptimizeRx Co. (NASDAQ:OPRX) – Investment analysts at B. Riley issued their Q1 2025 EPS estimates for shares of OptimizeRx in a research report issued on Wednesday, March 12th. B. Riley analyst A. Schock anticipates that the company will earn ($0.34) per share for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for OptimizeRx’s current full-year earnings is ($0.33) per share. B. Riley also issued estimates for OptimizeRx’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.19 EPS and FY2025 earnings at ($0.27) EPS.

Several other research analysts also recently commented on OPRX. Royal Bank of Canada restated a “sector perform” rating and issued a $6.00 target price (down previously from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Stephens began coverage on shares of OptimizeRx in a research report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price objective for the company. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 target price on shares of OptimizeRx in a report on Thursday, February 6th. Finally, Lake Street Capital reissued a “buy” rating and issued a $11.00 price target on shares of OptimizeRx in a report on Tuesday, December 24th. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.06.

OptimizeRx Price Performance

OptimizeRx stock opened at $8.27 on Monday. The firm has a market capitalization of $152.34 million, a P/E ratio of -6.22 and a beta of 1.31. OptimizeRx has a one year low of $3.78 and a one year high of $14.13. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23. The business has a fifty day moving average price of $5.58 and a 200-day moving average price of $5.90.

Institutional Trading of OptimizeRx

Institutional investors and hedge funds have recently made changes to their positions in the stock. Janney Montgomery Scott LLC bought a new position in OptimizeRx in the third quarter valued at $810,000. Quest Partners LLC boosted its holdings in shares of OptimizeRx by 15,965.6% in the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after purchasing an additional 9,739 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after purchasing an additional 2,414 shares during the last quarter. Barclays PLC raised its holdings in shares of OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after buying an additional 21,060 shares in the last quarter. Finally, Bullseye Asset Management LLC lifted its position in OptimizeRx by 55.6% in the 3rd quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock worth $1,652,000 after buying an additional 76,458 shares during the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.